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Abstract
To elucidate the role of ETS gene fusions in castration-resistant prostate cancer (CRPC), we characterized the tran-
scriptome of 54 CRPC tumor samples from men with locally advanced or metastatic disease. Trefoil factor 3 (TFF3)
emerged as themost highly differentially regulated genewith respect to ERG rearrangement status and resistance to hor-
mone ablation therapy. Conventional chromatin immunoprecipitation (ChIP)–polymerase chain reaction andChIP followed
byDNAsequencing (ChIP-seq) revealed direct binding of ERG toETSbinding sites in the TFF3promoter inERG-rearranged
prostate cancer cell lines. These results were confirmed in ERG-rearranged hormone-naive prostate cancer (HNPC) and
CRPC tissue samples. Functional studies demonstrated that ERG has an inhibitory effect on TFF3 expression in hormone-
naive cancer but not in the castration-resistant state. In addition, we provide evidence suggesting an effect of androgen
receptor signaling on ERG-regulated TFF3 expression. Furthermore, TFF3 overexpression enhances ERG-mediated cell
invasion in CRPC prostate cancer cells. Taken together, our findings reveal a novel mechanism for enhanced tumor cell
aggressiveness resulting from ERG rearrangement in the castration-resistant setting through TFF3 gene expression.
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Introduction
Most patients with locally advanced or metastatic prostate cancer re-
ceiving androgen deprivation therapy (ADT) progress to a castration-
resistant state that leads to death. The systemic treatment options for
castration-resistant prostate cancer (CRPC) are limited. Docetaxel-
based chemotherapy is the only therapy proven by randomized trials
to provide a modest 2- to 3-month survival benefit [1,2]. The lack of
effective treatment reflects a poor understanding of the molecular un-
derpinnings of CRPC.
Most prostate cancers harbor a recurrent ETS gene fusion character-
ized by a rearrangement between the 5′ regulatory elements of an
androgen-regulated gene and the coding region of a member of the
ETS gene family of transcription factors, resulting in an androgen-
driven expression of the ETS transcription factor [3]. The most com-
mon rearrangements involve the ETS transcription factor ERG and
one of three known 5′ androgen-regulated promoters: TMPRSS2,
SLC45A3, and NDRG1 [4]. Fifty percent of all prostate cancers harbor
one of these rearrangements. A recent study [5] demonstrated that tran-
scription regulation differs based on the androgen context. In support
of this, Yu et al. [6] have recently characterized the genome-wide loca-
tion of AR, ERG, and epigenetic marks. In their study, they found that
AR-bound genes were enriched with a large number of ERG-associated
genes and, similarly, that ERG is bound to more than 90% of AR-
bound genes, showing a high degree of co-occupancy. Moreover, their
study showed that ERG physically interacts with AR and can inhibit its
binding and its activity leading to a disruption of AR-mediated differ-
entiation of the prostate.
It has been shown that ERG is expressed at comparable levels in
ERG-rearranged hormone-naive prostate cancer (HNPC) and CRPC
[7]. To gain insight into how ERG-rearranged prostate cancers differ
molecularly from nonrearranged cancers, we initially interrogated the
transcriptome of 354 HNPC tumor samples, leading to the key obser-
vation that estrogenic signaling through an estrogen-binding site on the
TMPRSS2 promoter might explain continued expression of the fusion
transcript in a CRPC state [8].
Encouraged by these results, and to gain insight into how ERG re-
arrangement may lead to a distinct perturbation of regulatory pathways,
we investigated the expression profile of CRPC. Few expression array
studies have explored CRPC owing to the difficulty of obtaining frozen
tissue, and they were limited to a small number of samples [9–12]. To
overcome this challenge, we exploited the newly developed comple-
mentary DNA–mediated annealing, selection, extension, and ligation
(DASL) expression profiling platform for formalin-fixed paraffin-
embedded (FFPE) tissue, which allowed us to interrogate the expression
of more than 6000 transcriptionally informative genes [8] in transure-
thral resection biopsies of CRPC patients.
Materials and Methods
Patients and Samples
The cohort initially included 83 transurethral resection of prostate
samples from 59 patients who had been treated with one or multiple
ADT protocols at McGill University Hospitals (Montreal, Canada).
The clinical characteristics of 35 patients with complete information
are summarized in Table W1. The castration-resistant status was deter-
mined clinically based on the prostate-specific antigen (PSA) levels and
disease progression under treatment. Archived FFPE samples were re-
trieved with approval from the local institutional review boards. Using
a recently described protocol [8], tissue cores at diameters of 0.6 and
1.5 mm were obtained from areas containing high-density tumor and
were subjected to tissue microarray (TMA) construction and RNA ex-
traction, respectively.
Fresh-frozen metastatic prostate cancer tissue samples were obtained
from the University of Michigan Rapid Autopsy Program [13]. Frozen
HNPC samples were obtained from men with localized and locally
advanced prostate cancer who underwent radical prostatectomy as a
monotherapy and were processed as previously described [4]. Publicly
available expression profiling data from the tumor samples of 354 men
with HNPC (clinical stage T1-T2, N0, Mx) followed on a Watchful
Waiting protocol were also used in the analysis of current study (GEO
series accession number GSE8402) [8].
Fluorescent In Situ Hybridization
ERG rearrangement was evaluated using a break-apart probe assay on
TMAs as previously described [14]. Trefoil factor 3 (TFF3) rearrange-
ment was assessed by applying a break-apart probe set consisting of
the Biotin-14-dCTP-labeled BAC clone RP11-891L10 (eventually
conjugated to produce a red signal) and the digoxigenin-dUTP–labeled
BAC clone RP11-53A21 (eventually conjugated to produce a green sig-
nal), both spanning the neighboring centromeric and telomeric region
of the TFF3 locus, respectively. BAC clones were selected from the
March 2006 build of the human Genome using the UCSC Genome
Browser and were obtained from the BACPAC Resource Center, Chil-
dren’s Hospital Oakland Research Institute (Oakland, CA).
Morphologic Evaluation
Histologic features of prostate cancer after ADTwere assessed using
a previously described scoring system that was shown to be highly re-
liable for determining the effects of hormonal treatment [15]. Certain
morphologic features such as small cell carcinoma (neuroendocrine)
differentiation were annotated for the cases.
Expression Profiling
Complementary DNA–mediated annealing selection and ligation
assay (DASL) (Illumina, San Diego, CA) was used to profile CRPC
tumor samples available in FFPE blocks. The DASL method exponen-
tially amplifies transcripts of interest and has high sensitivity for genes
with low expression levels. The platform used for this study consists of
four DASL assay panels (DAP) covering approximately 6000 genes
selected based on the evaluation of more than 250 microarray data sets
(database available at http://www.broad.mit.edu/cancer/pub/HCC).
This 6K DASL platform has been recently used to evaluate more than
350 clinically localized prostate cancer [8] and 307 cases of hepato-
cellular carcinoma [16]. We jointly analyzed the CRPC cohort from
Montreal and the HNPC Swedish Watchful Waiting cohort [8]. To
resolve the potential study design confounder (expression data for the
CRPC and HNPC Swedish cohort were generated at different time
in different centers), we used the gene expression data from nine clini-
cally localized prostate cancer (experiment control samples), which
were profiled together with the CRPC cohort in the same experiment.
All statistical analyses were performed with the R statistical software
(www.r-project.org). For a more detailed description of data processing
and analyses, please see Supplemental Materials and Methods. At the
completion of the morphologic evaluation and of the gene expression
profiling data quality assessment, interpatient and intrapatient sample
correlations were assessed. In this process, when more than one tumor
focus was present for a given patient from a single biopsy or multiple
biopsies, we retained data only from foci with intrapatient differences
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in gene expression (correlation coefficient < 0.7). Fifty-four tumor sam-
ples from 52 individuals passed these quality control measures.
Immunohistochemistry and Quantification
Serial sections of TMAs containing the CRPC cases and additional
localized HNPC cases were prepared. Immunohistochemical staining
of TFF3 and AR were performed on a Bond Max Autostainer (Leica
Microsystems, Bannockburn, IL) using the following antibodies: anti-
TFF3 (clone 15C6, 1:250; Calbiochem, Gibbstown, NJ) and anti-AR
(clone F39.4.1, 1:800; Biogenex, San Ramon, CA). Briefly, sections
were deparaffinized, and endogenous peroxidase was inactivated. Anti-
gen retrieval was accomplished using the Bond Epitope Retrieval Solu-
tions (Leica Microsystems) at 99 to 100°C for 20 minutes. The sections
were then incubated sequentially with the primary antibody for 25min-
utes after the primary for 15 minutes and polymer for 25 minutes
followed by colorimetric development with diaminobenzidine for
10 minutes. The Ariol imaging system (Applied Imaging, San Jose,
CA) was used for quantification of protein expression in TMAs.
Immunohistochemistry data were analyzed separately for the two arrays
containing HNPC and CRPC, respectively.
Cell Lines
The prostate cell lines including benign epithelial cells RWPE-1,
cancer cell lines (VCaP, LNCaP, 22Rv1, PC3, and DU145), and pros-
tate stromal cells PrSc, as well as the embryonic kidney epithelial
cells HEK-293 were purchased from ATCC (Manassas, VA) and main-
tained according to the manufacturer’s protocols. We used pLenti6.3/
V5-TOPO plenti6.3/V5-GW/lacZ vectors (Invitrogen, Carlsbad,
CA) to generate stable HEK-293 cells expressing either the FLAG
(DYKDDDDK)–tagged truncated ERG (HEK-293tERG) or LacZ
(HEK-293LacZ), respectively. To generate stable tERG-expressing
RWPE-1 and DU145 cells, the tERG-FLAG open reading frame was
subcloned into a retroviral virus expression vector (pBABE; a kind gift
from Dr. William Hahn from the Broad Institute and the Dana Farber
Cancer Center), which is equipped with an IRES-driving green fluores-
cent protein (GFP) expression. For transient overexpression of TFF3, we
obtained the pcAGGS-TFF3 expression vector and pcAGGS control
vector (kind gifts from Dr Steven Itzkowitz, Mount Sinai School of
Medicine, New York, NY). These vectors were transfected into
DU145-tERG orDU145-GFP cells usingTransIT-Prostate Transfection
Kit (Mirus Bio,Madison,WI) following themanufacturer’s instructions.
TFF3 expression messenger RNA (mRNA) was assessed, and invasion
assay was performed 48 hours after transfection as described below. VCaP
cells were treated with 50 nM small interfering RNA (siRNA; scram-
bled or against the TFF3 mRNA) using Mirus TransIT-TKO and
OPTI-MEMI (Mirus Bio LLC, Madison, WI) serum-free medium.
Real-time Quantification of ERG and TFF3 mRNA
After RNA extraction, the quality of RNA was assessed using the
Bioanalyzer 2100 (Agilent Technologies, Inc, Santa Clara CA). Quan-
titative reverse transcription–polymerase chain reaction (RT-PCR) was
performed using Power SYBR Green RNA-to-Ct (Applied Biosystems,
Foster City, CA) following the manufacturer’s protocol. Each sample
was run in triplicate. The amounts of target genes were calculated rela-
tive to the reference geneHMBSusing the comparativeC t method (ABI
Bulletin 2; Applied Biosystems). For this, raw C t values for ERG or
TFF3 were first normalized using the average C t values obtained for
HMBS and then calibrated using normalized C t values obtained from
one of the control cell lines (HEK-293LacZ). The primer sequences for
ERG, TFF3, and HMBS are as follows: 5′-CGCAGAGTTATCGTG-
CCAGCAGAT-3′ and 5′-CCATATTCTTTCACCGCCCACTCC-3′
(ERG); 5′-TGTGCCGTGCCAGCCAAG-3′ and 5′-CTGGAGGT-
GCCTCAGAAGGTG-3′ (TFF3); 5′-CCATCATCCTGGCAA-
CAGCT-3′ and 5′-GCATTCCTCAGGGTGCAGG-3′ (HMBS).
Chromatin Immunoprecipitation and Quantitative PCR
We used MatInspector (version 8.0; Genomatix Software GmbH,
Munich, Germany) [17] to identify ETS family transcription factor
binding sites in the 878 bp of genomic sequence near the transcription
start site for TFF3 in silico. This region included 626 bp of upstream
and 252 bp of downstream sequence. Briefly, 75 × 106 HEK-293tERG
or HEK-293LacZ cells were washed in PBS twice and then fixed using
1% formaldehyde for 10 minutes at room temperature and quenched
using 125mM glycine. The cells were centrifuged, and the cell pellet was
resuspended in 2 ml of dilution buffer (165 mM NaCl, 0.01% SDS.
1.1% Triton X-100, 1.2 mM EDTA pH 8.0, 16.7 mM Tris-HCl pH
8.0, 1 mM phenylmethylsulfonyl fluoride). Protein-bound chromatin
was fragmented by sonication for 10 minutes (cycles of 30-second pulses
of sonication followed by 30 seconds of rest). Equal volumes of chromatin
were immunoprecipitated with either mouse anti-FLAG conjugated
agarose (Sigma, St Louis,MO) or rabbit anti-ERG (GeneTex, Inc, Irvine,
CA), rabbit anti-actin (Cell Signaling, Danvers, MA), or mouse immu-
noglobulin G (IgG) antibodies/protein A agarose (Sigma). After extensive
washing, the DNA was eluted using 100 mM NaHCO3 and 1% SDS,
and the cross-links were reversed using 300 mM NaCl at 65°C for
16 hours. The eluted DNA was purified using Qiagen PCR Qiaquick
kit following the manufacturer’s protocol. For quantitative PCR am-
plification, we used the ABI 7500fast system (Applied Biosystems Life
Technologies Corporation, Carlsbad, CA) and the relative standard curve
method in a 96-well format. For this, we designed primer sets that target
each of the three ETS bindings sites identified in the TFF3 promoter
(Table W2). Two microliters of either eluted DNA or a 1:10 dilution
of the input chromatin preparation from each cell line was assayed
to calculate the percentage of enrichment. Primers targeting a copy
number–stable chromosomal region in ARHGEF11 (chr1:155205397-
155205600, hg18) were used as a negative control as previously described
[18]. Input DNAwas also analyzed at five concentrations (0.004-40 ng)
to generate the standard curve per primer pair and per 96-well plate. All
reactions were run in triplicates. For chromatin immunoprecipitation
(ChIP) using the tissue samples, we followed the protocol described below
for ChIP-seq experiments with one modification. Frozen tissue cores or
eight 20-μm sections were chopped into small pieces, fixed in 1% formal-
dehyde, quenched with glycine as described below, and homogenized to
disaggregate the tissue. Otherwise, ChIP was performed using either
mouse anti-FLAG–conjugated agarose (Sigma) or rabbit anti-ERG
(GeneTex, Inc), rabbit anti-actin (Cell Signaling), or mouse IgG anti-
bodies/protein A agarose (Sigma) essentially as previously described [19].
ChIP-seq
VCaP or LNCaP cells were grown in RPMI supplemented with
10% FBS and Glutamax to 90% confluence. Cells were harvested for
ChIP using an anti-ERG antibody (sc-543x; Santa Cruz Biotechnology,
Santa Cruz, CA) or IgG control as previously described [20]. ChIP-seq
was performed using Illumina Genome Analyzer according to stan-
dard manufacturer’s procedures. The raw sequencing image data were
analyzed by the Illumina analysis pipeline, aligned to the unmasked
human reference genome (NCBI v36, hg18) using the ELAND soft-
ware (Illumina) to generate sequence reads of 25-35 bps. ChIP-enriched
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binding peaks were defined by HPeak (http://www.sph.umich.edu/csg/
qin/HPeak/).
Cell Invasion and Migration Assays
Cells were harvested with trypsin/EDTA and resuspended in com-
plete medium with 10% fetal calf serum. After centrifugation, the cells
were washed with serum-free medium and centrifuged. Cell pellets
were resuspended in serum-free medium, and cell counts were per-
formed in a hematocytomer chamber to dilute the cells to a concentra-
tion of 2 × 105 cells/ml. Boyden chambers coated with Matrigel (BD
Biosciences, San Jose, CA) or with 8-μm pore inserts (BD Biosciences)
were used for the invasion assay or the migration assay, respectively.
This was performed by placing 5 × 104 cells into the upper chamber
and 0.75 ml of medium containing 10% fetal calf serum into the lower
chamber. After a 24- or 48-hour incubation at 37°C, the cells attached
to the upper side of the membrane were removed with cotton swabs
and cells that migrated into the lower side of the membrane were fixed
with 10% formaldehyde, stained with Coomassie blue and washed with
PBS. Micrographs were taken with a Retica 1300i CCD camera on a
Nikon eclipse 80i microscope (Nikon, Melville, NY) using a 4× objec-
tive lens. For a given experiment, each assay was performed in tripli-
cate. Cell number per field was counted and analyzed using GraphPad
Prism (GraphPad Software, Inc., La Jolla, CA). For the VCaP siRNA
knock-down/invasion assay, 1.5 × 105 cells were plated into the Boyden
chambers, and the lower chamber contained NIH-3T3 medium sup-
plemented with 10 ng/ml of epidermal growth factor and 5 ng/ml of
insulin-like growth factor and incubated for 72 hours. The membranes
were processed as described above.
Results
Histologic Characterization of CRPC
The castration-resistant status of prostate cancer patients was deter-
mined clinically based on rising PSA and/or other evidence of disease
progression while receiving ADT treatment. A previous work from
Mostaghel et al. [21] showed that despite 9 months of ADT treatment,
complete intratumoral blockade of androgen-regulated gene expres-
sion was not achieved. To ensure that our study would focus on estab-
lished molecular alterations due to ADT, not only did we select CRPC
samples from patients that had been treated for more than 8 months
(range = 8-92 months, median = 32 months; Table W1), we also
evaluated the hormonal treatment effect of each case using previously
described histologic criteria [15]. The complete range of histologic fea-
tures is represented in Figure 1A. We identified 47 samples with un-
equivocal ADT effect (Figure 1A, first three panels) and 7 samples of
small cell neuroendocrine carcinoma of the prostate, which commonly
displays minimal morphologic change with ADT (Figure 1A, far right
panel ), a total of 54 samples from 52 patients, to be included in the
transcriptome profiling analysis.
We next determined the ERG rearrangement status of these CRPC
using an ERG break-apart fluorescent in situ hybridization assay. Of
54 samples, 18 (33%) demonstrated the ERG rearrangement either
through interstitial deletion (n = 12) or through insertion (n = 8). Four
of the seven small cell carcinoma samples demonstrated ERG rearrange-
ment (Figure 1B), supporting their prostatic origin [22]. It has been
suggested that ERG rearrangement may not be associated with an ac-
tive fusion transcript with disease progression [23]. We investigated
the levels of three main TMPRSS2-ERG fusion transcripts (type I, III,
Figure 1. CRPC is morphologically and genetically heterogeneous and harbors ERG rearrangement in a subset of cases. (A) Distinct morpho-
logic types of CRPC including adenocarcinoma with unequivocal hormone treatment effect (A, first three panels) and small cell carcinoma
minimal hormone treatment effect (A, far right panel). (B) Small cell prostate carcinomas harborERG rearrangement occurring through insertion
(left panel) or deletion with accompanying polysomy (right panel). Scale bar, 1 μm. (C) Heat map of the supervised gene expression differen-
tiation analysis results between ERG-rearranged and nonrearranged CRPC. The 18 genes (FDR < 20%) are ranked according to the levels of
expression alterations. Three genes (in light blue font) overlap with a recently described 87 gene signature from ERG-rearranged HNPC.
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and VI) [24] in CRPC cases (Figure W1). Among 19 cases of ERG-
rearranged CRPC, 14 (73%) showed detectable ERG fusion transcripts.
Expression Profiling Using DASL
Having identified and characterized the CRPC cases in the cohort,
we undertook expression profiling of the FFPE tissue using DASL
[8,16] where we applied previously described criteria for high-quality
gene expression data [8] and interpatient and intrapatient correlation
analysis (see Materials and Methods).
Using a supervised approach to investigate genes differentially ex-
pressed in ERG-rearranged CRPC, 18 differentially expressed genes
(false discovery rate [FDR] < 20%,Wilcoxon rank sum test) were iden-
tified based on ERG rearrangement status (Figure 1C).
To explore the nature of the molecular signature due to ADT, we
compared these 18 genes to a previously identified 87 gene signature
of clinically localized ERG-rearranged HNPC cases from a Watchful
Waiting Cohort [8]. Of 18 genes, 3 overlapped (Figure 1C , probability
of detecting three common genes by chance is equal to 0.0045), namely
GP1BB, RFX1, and TFDP1, suggesting that, although many molecular
mechanisms crucial for ERG-rearranged prostate cancer are altered in
CRPC, some ETS rearrangement–related molecular regulations are
maintained independent of hormonal state. Among the top three dif-
ferentially regulated genes in ERG-rearranged CRPC was PFKFB3,
a unique member of the enzyme family 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase that regulates the cellular concentration of
fructose-2,6-biphosphate (F2,6BP) (see Supplemental Discussion).
ERG-Rearranged HNPC and CRPC Show Inverse Patterns
of Differential Regulation of TFF3
To examine the molecular signaling of ERG-rearranged prostate can-
cer in the context of androgen-enriched or androgen-deplete environ-
ments, we performed statistical interaction analysis on the expression
profiling data from 408 tumor samples (354 HNPC and 54 CRPC)
modeling ERG status and hormonal treatment status. We identified
25 genes with significantly altered expression patterns in CRPC com-
pared with HNPC that were related to the ERG rearrangement status.
These genes may be related to the role of ERG rearrangement during
the progression from HNPC to CRPC (Table 1).
TFF3, previously identified as a putative prostate cancer biomarker
with overexpression observed in only a subset of cases [25,26], was
the top-ranked gene. Our analysis identified a significant expression pat-
tern change between CRPC and HNPC in relation to ERG rearrange-
ment (P = 0, permutation test; see Combined Analysis of CRPC and
HNPC in Supplemental Materials and Methods). In HNPC, TFF3
was significantly downregulated in ERG rearrangement–positive com-
pared with ERG-negative tumors (P = 3.1e − 09, for a test of differential
expression by Wilcoxon rank sum test), but this pattern was altered in
an opposite direction in CRPC with ERG-rearranged cases showing a
tendency for up-regulation (P = .055, for a test of differential expres-
sion by Wilcoxon rank sum test). We confirmed the two patterns at
the protein level by immunohistochemistry quantified using an auto-
mated imaging system (Figure 2, A and B; P = .03 for the test of inter-
action through permutations as described in the Materials andMethods
section; P = .07 for Wilcoxon rank sum test comparing ERG rearrange-
ment in HNPC and P = .09 for the same in CRPC). These data sug-
gest that TFF3 expression is downregulated during the transition from
HNPC to CRPC for the ERG rearrangement–negative tumors. Inter-
estingly, we found that the highest levels of TFF3 protein in the ERG-
rearranged CRPC were in cases with undetectable or low AR levels
(0%-25% quartile of AR expression; Figure 2C ). This relationship
was not observed in HNPC (data not shown).
Similar to the expression of TFF3 in ERG-rearranged CRPC, we
also observed increased TFF3 expression in a prostate cancer cell line
derived from therapy-resistant metastatic prostate cancers harboring
ERG rearrangement and expressing AR (i.e., VCaP) but not in cell lines
without the rearrangement (i.e., LNCaP, PC3, and 22Rv1) or in pros-
tate stromal cells (i.e., PrSc; Figure 2D).
TFF3 Expression Is Directly Regulated by ERG
The three members of the TFF gene family are located near the
TMPRSS2 gene on chromosome 21q22.3, with TFF3 being the clos-
est at roughly 800 kb from the TMPRSS2 transcription start site (Fig-
ure 3A). To exclude the possibility that the down-regulation of TFF3
in ERG-rearranged HNPC is driven by a genomic alteration, we inter-
rogated a cohort of 18 HNPC cases on a test TMA using a dual-color
TFF3 break-apart fluorescent in situ hybridization assay and did not
detect TFF3 deletion or rearrangement (data not shown). By in silico
analysis, we identified three putative ETS family transcription factor–
binding sites within 878 bp of genomic sequence surrounding the
TFF3 transcription start site (Figure 3A and Table W2). On the basis
of results from a ChIP assay, we detected a direct interaction of ERG
to two of these three ETS binding sites (EBS1-3) in HEK-293 cell lines
overexpressing the truncated open reading frame of ERG (HEK-
293tERG) encoded by the most prevalent TMPRSS2-ERG fusion tran-
script type III (Figure 3B). Parallel ChIP using species-specific control
Table 1. Genes That Were Found to Be Highly Significant (P = 0, Permutation Test) Related to
ERG Rearrangement and Progression to CRPC under ADT Identified by the Interaction Model.
Gene Symbol P * (F†) P * (H†) Estimate‡ (F ) Estimate‡ (F ) Estimate‡ (F × H )
TFF3 0 .049791 −0.5166 −1.08341 1.012905
INPP4B .055974 .89646 −0.45506 −0.39481 1.355811
BSG .060216 .546415 0.007968 −0.03601 0.334732
HNRPH2 .088557 .74128 0.058647 −0.37028 0.629867
AZGP1 .16011 .951432 −0.3513 −0.40521 0.919148
PCBP1 .173117 .680504 0.012675 −0.17463 0.250093
SLC4A4 .186616 .147655 −0.42278 −1.25905 1.35686
PHKG2 .202698 .062971 0.014572 0.948933 −0.73296
CSRP1 .230435 .071665 0.007243 −0.83526 0.624356
CAPZB .303962 .49861 −0.00394 −0.57613 0.763955
LMAN1 .360658 .264247 −0.04036 −0.49036 0.617975
CAV1 .425037 .240416 −0.0102 0.210558 0.654177
SEMA3C .436939 .737742 −0.20679 −0.56852 0.844928
GLG1 .493471 .763193 −0.08542 −0.21319 0.899588
NAP1L4 .535457 .125271 0.111557 −0.15817 −0.4481
RBBP7 .675381 .090465 −0.19193 −1.01176 0.857275
ENO1 .689337 .84047 −0.02496 −0.05213 0.230198
RNASE4 .698196 .8256 −0.20992 −0.62507 1.060066
RPL13A .768596 .63122 −0.0518 −0.05548 0.380193
LDHA .785075 .814296 0.11248 0.283165 −0.47686
GNE .81904 .442845 −0.07524 −0.50476 0.56862
CA9 .847723 .763193 −0.1406 −0.25086 0.96787
MLLT1 .887444 .143074 −0.04602 0.099475 0.323797
ARD1A .931244 .502358 −0.0521 −0.00137 0.27497
PRPF4B .994072 .507388 0.077961 0.005466 −0.4533
*The P value (computed using the permutation test) corresponds to the test of its corresponding co-
efficient being equal to 0, representing the significance of each factor's contribution to the interaction
model (see Materials andMethods). Specifically, the F P value and theH P value correspond to test of
significance of the marginal effect of the ERG rearrangement status and hormone treatment status.
Testing the marginal effect means comparing the differential expression across two levels of a factor
irrespective of the levels of the other factor. For example, the marginal effect of ERG rearrangement
status would compare ERG rearranged cases to those not rearranged in both CRPC and HNPC.
†F,H , and F ×H correspond to the effects of ERG rearrangement (F ), ADT (H), and the interaction
between the two factors (F × H ), respectively.
‡The estimates correspond to the least square estimates for α, β, and γ in the interaction model (see
Supplemental Materials and Methods).
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antibodies was performed to assess the specificity of the ChIP assays
(Figure W2A). The nonbiased approach of ChIP followed by deep
sequencing (ChIP-seq) performed in VCaP cells (androgen receptor–
positive and harboring a TMPRSS2-ERG fusion) revealed specific
binding of ERG to a region that covers EBS2 and 3 in the proximal
TFF3 promoter (Figure 3C ). As a negative control, ChIP-seq of ERG
performed in LNCaP cells that do not harbor TMPRSS2-ERG gene fu-
sions detected background level enrichment with less than 700 peaks
(data not shown), in contrast to more than 40,000 ERG binding peaks
in VCaP cells. ERG binding was also observed at a distant site roughly
25 kb upstream of the transcription start site (Figure W2B). To deter-
mine whether ERG binds to these ETS sites in human samples, we per-
formed ChIP with HNPC or metastatic prostate cancer tissue samples
that harbor TMPRSS2-ERG gene fusions. Because of the limited
amount of material, we focused on the two ETS sites showing the high-
est level of binding in vitro. As with the cells lines, we found specific
binding of ERG to the TFF3 promoter compared with benign prostate
tissue (Figures 3D and W2C ).
We next examined the effect of ERG binding on the expression of
TFF3. In HEK-293tERG cells, the level of TFF3 is low compared with
the control cells (Figure 4A, left), suggesting an inhibitory effect of ERG
on TFF3 expression. However, knocking down the expression of ERG
fusion transcripts using short hairpin RNA (shRNA) molecules in
VCaP cells resulted in a decreased level of TFF3 expression, suggesting
an opposite effect of ERG in this cell context. VCaP cells are known
to not only harbor ERG rearrangement but also maintain androgen re-
ceptor expression [3]. We therefore wanted to examine the effect of
androgen signaling on TFF3 expression and test the hypothesis that
the regulation of TFF3 by ERG differs as a function of androgen sig-
naling. To this end, we generated stable RWPE-1 cells overexpressing
Figure 2. ERG-rearranged HNPC and CRPC show inverse patterns of differential regulation of TFF3 protein. (A) TFF3 protein expression as
determined by immunohistochemistry (IHC) shows an inverse pattern in HNPC (left panel) and CRPC (right panel) with respect to ERG re-
arrangement, consistent with the mRNA behavior. (B) Representative images of TFF3 protein expression in HNPC and CRPC samples in the
absence or presence of ERG rearrangement. (C) The expression of TFF3 in CRPC is higher in the cases with low AR expression as deter-
mined by IHC. Data are represented based on AR levels quartiles (Q1-Q4). Dot, outliers (1.5-3 interquartile range); asterisk, extreme values
(>3 interquartile range). (D) Quantification of TFF3 mRNA in prostate cell lines with (green) or without (blue) ERG rearrangement.
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GFP (control) or tERG (RWPE1-tERG; Figure W3). Treatment of
RWPE1-GFP cells with R1881, a synthetic androgen, led to an up-
regulation of TFF3 compared with cells grown in androgen-free me-
dium, which could be abrogated with bicalutamide. RWPE1-tERG
cells had much lower level of TFF3 expression than control cells likely
because of the inhibitory effect of ERG. Treatment with R1881 led to
a further down-regulation of TFF3 compared with cells grown in an
androgen-free medium. Treatment with R1881 together with the AR
antagonist bicalutamide restored TFF3 levels (Figure 4B).
TFF3 Promotes Invasion in CRPC Cells
To explore the potential function of TFF3 in CRPC, we overexpressed
ERG fusion transcripts with or without TFF3 coexpression in another
androgen-insensitive cell line DU145 that is negative for ERG rearrange-
ment (Figure 4C). DU145 represents another CRPC cell line but differs
from VCaP in that these cells are androgen-insensitive. Overexpression
of ERG lead to an increase of TFF3 mRNA levels consistent with the
results presented in Figure 4B. Consistent with previous studies of other
cell types [27,28], overexpression of ERG fusion transcripts alone re-
sulted in a heightened level of cell invasion (Figure 4D) but had no effect
on cell proliferation (data not shown). Interestingly, increasing the levels
of TFF3 in ERG-negative DU145 cells resulted in similar levels of cell
invasion. Combining ERG and TFF3 overexpression led to a further
enhanced level of cell invasion. In the hormone-insensitive VCaP cell
line, which harbors the TMRPSS2-ERG gene fusion, TFF3 mRNA is
significantly decreased after treatment with TFF3 siRNA compared
with scrambled control (Figure 4E). This decrease in TFF3mRNA after
siRNA treatment is associated with a significant decrease in cell invasion
(Figure 4F ).
Discussion
The current study is the first, to our knowledge, to systematically char-
acterize the molecular changes associated with ERG rearrangement in
CRPC. A major finding is the demonstration of distinct molecular
signaling in ERG-rearranged prostate cancer in the context of the
androgen environment. It has been shown that ADT leads to an in-
complete inhibition of androgen-regulated genes [21] while maintain-
ing AR expression at the transcript level [29]. On the basis of our
profiling data, we also found that AR mRNA is higher in CRPC versus
HNPC (P = 1.4e − 05, Wilcoxon rank sum test, data not shown). Our
data now extend this observation suggesting that this transcriptome
deregulation differentially occurs based on ERG rearrangement status.
A previous study by Hermans et al. [23] suggested that the ETS fu-
sion transcript is no longer produced after loss of the AR, where they
found four xenografts negative for AR did not express ERG, whereas
other members of the ETS family (namely, ETV4 and FLI1) were over-
expressed through an androgen-independent mechanism. Saramaki
et al. [30] also reported two AR-negative xenografts generated from
ERG-rearranged small cell carcinomas of the prostate that did not ex-
press ERG. However, other hormonally sensitive xenografts and clinical
tumor specimens they tested indeed showed elevated ERG expression
levels correlated with ERG rearrangement. In line with this finding,
Figure 3. ERG directly binds to the TFF3 promoter in vitro and in human prostate cancer samples and regulates its expression. (A) Schematic
representation of TFF3, TMPRSS2, and ERG positions on chromosome 21. The transcription start site for each gene is indicated with an
arrow. Below shows a scheme (not to scale) of the TFF3 gene (coding sequence in yellow) and the position of the three ETS binding sites
(EBS1-3, circles) relative to the transcription start site (arrow). (B) Bar graphs showing the amount of enriched DNA (relative to input chro-
matin preparation) for each EBS in the indicated cell lines after ChIP using either anti-FLAG (right) or anti-ERG (left) antibodies. (C) Chip-seq
data obtained from VCaP cells of the region of chromosome 21 that covers the TFF3 gene and ∼800 bp of upstream sequence. The lines
indicate the relative number of significant reads that mapped to the indicated region. The chromosome region is indicated above. The
normalized peak reads, 27.3, and the 6.4 cutoff reads (above which the peak signal is defined as significant) are shown on the left. The
circles below indicate the positions of the EBS1-3. (D) Bar graphs showing the amount of enriched DNA for EBS2 and three in the indicated
tissue sample after ChIP using anti-ERG (left) antibodies.
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most studies including the initial index case [3] and the current study
have found that gene fusion expression continues into the castration-
resistant state perhaps due to the incomplete inhibition. Works by
Nelson et al. [31] and Lin et al. [32] characterizing androgen response
genes place the 5′ fusion partners of ERG (i.e., TMPRSS2, SCL45A3,
and NDRG1) among the most androgen-responsive genes. One im-
portant implication is that ETS-rearranged prostate cancer may respond
more dramatically than rearrangement-negative tumors due to a higher
Figure 4. (A) Relative levels of ERG (green) and TFF3 (yellow) mRNA in HEK-293tERG cells (normalized to HEK-293LacZ cells; left) or in VCaP
cells (normalized to VCaP cells treated with shRNA against GFP; right) after ERG shRNA expression. The dotted line represents the
level corresponding to the expression in control cells. (B) Relative average levels of TFF3 mRNA in RWPE1-tERG (tERG +) or RWPE1-GFP
(tERG−) cells grown in androgen-free (charcoal-stripped, phenol red–free)mediumand treated 24 hourswith vehicle or 10 nMof the synthetic
androgen R1881 in the presence or absence of the AR antagonist 20 μMbicalutamide (Bical.). Expression levels were normalized to RWPE1-
tERG cells grown in androgen-free vehicle-treated conditions (dotted line). (C) Relative levels TFF3 (yellow) mRNA in DU145 cells stably over-
expressing tERG (ERG-positive) or GFP (ERG-negative) with or without transient overexpression of TFF3 (transient). The data was normalized
to DU145-GFP control cells. (D) Representative images of cells (left) and bar chart depicting the corresponding relative cell counts (right) ob-
tained from cells described in (C) at the completion of the invasion assay. (E) NormalizedmRNA expression of TFF3 in VCaP cells is effectively
reduced after exposure to TFF3 siRNA compared with control (scrambled siRNA molecule). (F) Reduction of TFF3 using siRNA significantly
decreases VCaP cell invasion comparedwith control. Representative areas of invasion are demonstrated (right side). For all experiments, error
bars demonstrate SD across triplicate experiments.
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addiction to hormonal regulation at any level. Reports have shown that
ERG rearrangement does not predict response to traditional hormonal
therapy [33,34]. However, this is not the case when a more complete
AR block is achieved as suggested by the results of a recent clinical trial
testing the ability of the potent CYP17 inhibitor, abiraterone, to de-
crease PSA levels greater than 90% in men with CRPC [35]. In this
phase 2 clinical trial, men with ERG-rearranged CRPC, as determined
by the evaluation of circulating tumor cells, responded significantly
more frequently than men without detectable ERG rearrangements.
Taken together, these observations support the hypothesis that ETS
rearrangements continue to play an important role in CRPC. Inter-
estingly, unlike AR gene amplification and PTEN loss, which were
heterogeneously altered within the circulating tumor cells isolated from
individual cases, all tumor cells in ERG-rearranged cases showed the
gene fusion, supporting the notion that the ERG rearrangement occurs
early in tumorigenesis and persists in CRPC [14,36].
Understanding how ERG directly regulates downstream targets is
an important step in developing targets to key signaling pathways. Sev-
eral recent studies have explored this using tumor cell lines [27,28,37].
We report for the first time that ERG directly regulates TFF3, a gene
located within 0.8 MB from TMPRSS2 on 21q22.3. Although TFF3
has previously been reported as a potential prostate cancer biomarker
overexpressed in a subset of primary and metastatic cases [25,26,38],
the underlying regulatory mechanism was entirely unknown. TFF3
has also been shown to regulate cell migration, invasion, and angio-
genesis in other cancer types (see Supplemental Discussion). Here we
show that in HNPC TFF3 is significantly downregulated in ERG-
rearranged cases. After exposure to ADT (CRPC cases), we observe
a strong reversal of this relationship; TFF3 is expressed at a higher
level in ERG-rearranged cases. We further demonstrate that in an
ERG-rearranged cell line (VCaP), TFF3 is expressed at a higher level
than in the ERG-nonrearranged cell line (LNCaP). Moreover, we show
that ERG binds to TFF3 gene promoter region ETS binding sites in
ERG-rearranged HNPC and CRPC tumor samples. Interestingly, the
work of Hollenhorst and Graves has shown that the different members
of the ETS family of transcription factors bind to the same ETS bind-
ing elements in gene promoters [39,40]. Therefore, because LNCaP
cells harbor a cryptic ETV1 rearrangement [41], it is possible that
ETV1 could bind to the same ETS binding sites located in the TFF3
promoter that was found to be bound by ERG in VCaP cells, but this
has yet to be tested. Whereas ERG exerts an inhibitory effect on TFF3
expression in HEK-293tERG cells, we found that ERG stimulates
TFF3 expression in VCaP cell lines, as well as in human CRPC sam-
ples, supporting a potential cross-talk between ERG rearrangement
and AR signaling in CRPC. However, we cannot rule out the influence
of other key factors that, by orchestrated interactions, may also con-
tribute to these differences observed between the different stages of
tumor progression. Because increased level of TFF3 might enhance
ERG-induced cell invasion as shown by our in vitro study, the differ-
ent levels of TFF3 expressed in CRPC under the influence of ERG
and AR signaling might thus alter the spread of tumor cells. The mecha-
nisms underlying the observation that ERG directly regulates TFF3 in
HNPC and CRPC and how TFF3 affects the pathogenesis of CRPC
warrant investigation.
Therefore, based on ChIP-PCR, ChIP-seq, knock-in, and knock-
down shRNA in vitro data, we find that ERG regulates TFF3 expres-
sion by directly binding to ETS binding sites in the TFF3 promoter
and that ERG exerts dual activities on TFF3 regulation depending on
the level of androgen signaling. Our results further support the idea
first suggested by Yu et al. [6] that ERG is hijacking AR-mediated pros-
tate cell maintenance as we show that, in the context of low AR activity,
ERG is inducingTFF3 expression, which, in turn, results in an increased
invasive potential of CRPC cells. In summary, TFF3 is a direct molec-
ular target of ERG and is regulated in a context related to hormonal
status and increases the invasive potential of CRPC cells. These observa-
tions suggest that understanding ETS rearrangement-related molecular
alterations will be important in the interpretation of ongoing ADT clini-
cal trials and in the development of novel therapeutics for CRPC.
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Supplemental Materials and Methods
Computational and Statistical Data Analysis of Expression
Profiling Data
Normalization and data filtering/quality control. The expression
values generated from the DASL 6K platform are corrected for back-
ground noise using the Beadstudio software (Illumina, San Diego, CA).
A detection P value is calculated for each probe by comparing its in-
tensity to the rank of the negative controls. Lower P values pertain to
reliable expression data. We considered as missing all the gene ex-
pression values that did not meet a P value threshold of .05. We then
excluded from further analysis all the samples with more than 55%
of missing values (six samples excluded). The same criterion was ap-
plied for the selection of genes (1603 genes excluded). Data were then
logarithm (base 2)–transformed. To correct for an array effect, each
sample for each DAP was median-centered. To correct for a DAPeffect,
all samples belonging to a DAP was median-centered. When multiple
samples were profiled from the same patient (see cohort description),
the similarity of the expression profile was evaluated pairwise using the
concordance correlation coefficient [1]. If an intrapatient sample pair
had a concordance correlation coefficient greater than 0.7, the sample
with more reliably expressed genes was retained for further analysis.
This resulted in a total of 54 samples from patients and 4541 genes.
Differential expression analysis. Wilcoxon rank test with a two-
sided alternative was used to evaluate the differential expression of genes
with respect to ERG rearrangement. FDR was calculated using the pro-
cedure of Benjamini and Hochberg [2], and genes with FDR less than
20% are reported.
Combined analysis of CRPC and HNPC. Adding the localized
samples to the CRPC samples during the gene expression profiling ex-
periment is critical for the CRPC and HNPC joint analysis as it allows
us to estimate the confounding effect. The CRPC and control samples
expression data were q-splined together with the median array as the
target. Similar q-spline normalization was performed for the Swedish
HNPC cohort. We considered the following model for the analysis
of variance for each gene: log2(S gi) = μg + δgEgi + αgF gi + βgH gi +
γgHgiFgi (E , F, and H correspond to the effects of experiment, ERG
rearrangement status, and ADT, respectively. HF represents the inter-
action between ERG rearrangement status and ADT. The subscripts
g and i correspond to gene and sample, respectively). To account for
deviation from normality of the combined data, we performed permu-
tation tests to assess the significance of the variance components. Per-
mutations were performed on the raw data labels. Although permuting
residuals can yield more power, the gain in power is marginal [3].
TMPRSS2-ERG Fusion mRNA Assay
TMPRSS2-ERG gene fusion mRNA and PSAmRNAwere quantified
using magnetic target capture (purification of target mRNA by hybridi-
zation to magnetic particles through target-specific oligonucleotides),
transcription-mediated amplification (amplification of target RNA
sequences), and a hybridization protection assay (specific detection of
amplification products by use of target-specific acridinium ester (AE)–
labeled probes) as described by Groskopf et al. [4]. Three TMPRSS2-
ERG splice variants were targeted: TMPRSS2-ERGa, b, and c [5], also
known as types III, I, and VI, respectively [6]. Amplification primers
for TMPRSS2-ERGa mRNA were located in TMPRSS2 exon 1 and
ERG exon 4 yielding an amplification product of 117 nucleotides. The
TMPRSS2-ERGb assay used amplification primers in TMPRSS2 exon 1
and ERG exon 2 yielding an amplification product of 109 nucleotides.
The TMPRSS2-ERGc assay used primers in TMPRSS2 exon 2 and
ERG exon 4, yielding an amplification product of 84 nucleotides. The
AE probes for each TMPRSS2-ERG splice variant spanned the junc-
tion between the two exons. Primers for PSA targeted exons 2 and 3 of
the PSA mRNA, and the AE probe spanned the exon 2/3 junction.
Calibrators and controls consisted of TMPRSS2-ERG or PSA in vitro
transcripts (IVTs) in detergent solution. The TMPRSS2-ERGa, b, and
c IVTs were prepared from plasmids provided by A. Chinnaiyan of
the University of Michigan [5]. IVT copy levels were determined by
A260. Assays were performed at Gen-Probe Incorporated (San Diego,
CA) using DTS 400 Systems; the assay protocol uses the reagent addi-
tion volumes and incubation times and temperatures specified in the
APTIMA COMBO2 package insert and as described in Groskopf
et al. [4]. PSA mRNA was used to normalize for the total amount of
prostate-specific mRNA in each sample. Samples with less than 500 cop-
ies ofPSAmRNAper 10 ng of total RNAwere considered invalid because
of insufficient mRNA for analysis.
Supplemental Discussion
Among the top three differentially regulated genes in ERG-rearranged
CRPC (Figure 1F) is PFKFB3, a unique member of the enzyme family
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase that regulates
the cellular concentration of fructose-2,6-biphosphate (F2,6BP). The
steady-state concentration of F2,6BP controls the overall rate of glycoly-
sis by allosterically activating phosphofructokinases, enzymes that me-
diate a key rate-limiting step of glycolysis. In contrast to other family
members, PFKFB3 has the highest kinase-phosphatase activity ratio,
and up-regulation significantly promotes glycolysis [7]. The fact that
PFKFB3 was identified as one of the most significantly upregulated
genes in ERG-rearranged CRPC indicates that increased glycolysis
might be a feature of this subset of CRPC. It has long been established
that some tumors have elevated glycolytic rates at even normal oxygen
tension and are thus more reliant on this pathway for cell growth, a
phenomenon referred to as the Warburg effect. Enhanced glycolysis is
also an important mechanism regulated by hypoxia-inducible factor 1
signaling in fast-growing tumors to adapt to hypoxia. The presence of
a significantly higher level of PFKFB3 in concert with many enzymes
mediating glycolysis, as described in this current study, suggests that
ERG-rearranged CRPCs are reliant on this pathway and may have a
selective growth advantage in an oxygen poor state, but further work
is needed to validate this hypothesis.
The function of TFF3 in prostate cancer has not been well studied.
Trefoil factors constitute a family of extracellular peptides (TFF1, 2,
and 3) initially identified in the gastrointestinal tract that contain dis-
tinctive cystine-rich “trefoil” domains and are resistant to proteolytic
degradation. In colon cancer cell lines, TFF3 is known to activate the
nuclear factor κB or STAT3 signaling pathways to regulate cell migra-
tion, invasion and angiogenesis [8,9]. Previous studies on the tran-
scriptional regulation of TFF3 have revealed that hypoxia-associated
hypoxia-inducible factor 1 activation can induce TFF3 expression by di-
rectly binding to a responsive element in the TFF3 promoter [10]. In
addition, phosphatidylinositol 3-kinase and Akt activation can promote
the expression of TFF3 [11]. TFF3 was also identified as a steroid-
responsive gene in breast cancer [12], where its expression was related
not only to ER but also to AR [13]. On the basis of in vitro studies, we
show that restoring the level of TFF3 in cells perturbs ERG-induced
cell invasion.
One can also speculate that ETS rearrangement status alone or in
the context of other genetic alterations, such as PTEN mutations
[14,15], begin to define molecularly distinct subclasses of prostate can-
cer. We previously suggested that ERG-rearranged HNPC can activate
estrogenic signaling for maintenance of tumor growth [16], which was
recently supported by a study from Jhavar et al. [17]. The finding that
TMPRSS2 harbors an ER binding site and is regulated by ER-α sug-
gests a gene fusion specific growth advantage in certain settings. We
imagined that ER signaling might play a more important role in the
setting of ADT. The current study would suggest that context-specific
differences based on gene fusion status could provide important insight
into therapeutic targeting, analogous to defining breast cancers based
on ER, PR, and HER-2/neu receptor status.
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Figure W1. Expression of ERG fusion transcripts in CRPC. Bar graph
of quantified transcripts. The normalized level of ERG fusion tran-
script with higher expression in each sample is plotted after natural
logarithm transformation. The level of AR evaluated by immuno-
histochemistry, the types of ERG rearrangement, and the presence
of small cell carcinoma (SC) features are annotated below. AR: gray
shades indicate quartiles of expression (lightest gray corresponds to
the lowest quartile). ERG rearrangement: light green, rearrangement
through translocation; dark green, rearrangement through deletion.
SC: purple indicates SC carcinoma.
Table W1. Clinical Characteristics of 35 Patients with CRPC in the Current Study.
Age (years)
Range 56-94
Median 73
Gleason score at initial diagnosis
≤6 4 (11%)
7-8 13 (37%)
9-10 18 (52%)
Primary treatment
Radical prostatectomy 2 (5%)
Radiation + ADT 5 (14%)
ADT 28 (80%)
ADT protocols
Orchiectomy 6 (17%)
LHRH 4 (11%)
LHRH + antiandrogens 25 (72%)
Time to development of resistance to ADT (months)
Range 8-92
Median 32
PSA level at TURP (ng/ml)
Range* 0.1-4537
Median 34
TURP indicates transurethral resection of prostate.
*Patients without biochemical recurrence (PSA level elevation) were clinically diagnosed as CRPC
based on clinical evidences of disease progression (i.e. newly developed metastatic foci).
Table W2. Primer Sets Targeting Each of the Three ETS Binding Sites (EBS) Identified in the TFF3 Promoter and Control Primer Set Targeting ARHGEF.
Name Gene Location to TSS Predicted ETS Site Sequence
TFF3 EBS-1 f TFF3 −375 −296 to −316 AAACTGTCTGGGAGCTTGAC
TFF3 EBS-1 r TFF3 −252 CTCAGGACTCGCTTCATGG
TFF3 EBS-2 f TFF3 −61 −23 to −43 CACATCCGCTCCCCAGTAG
TFF3 EBS-2 r TFF3 78 GGCTGCTCCTGTTCTCTCC
TFF3 EBS-3 f TFF3 47 +107 to +131 TTTCAATCAATTCATTTCATCCAC
TFF3 EBS-3 r TFF3 179 GAGACAGGCAGCTCTGAG
AREGH f AREGH NA NA TCTCTGCTCCCTCACTCTCAA
AREGH r AREGH NA NA TGTGCCTCTTCCATCGTTCT
NA indicates not applicable.
Figure W2. ERG directly regulates the expression of TFF3. (A) Bar graphs showing the amount of enriched DNA (relative to input chromatin
preparation) for each EBS in HEK-293tERG and HEK-293LacZ after ChIP using mouse anti-FLAG or mouse IgG antibodies. (B) Chip-seq data
obtained from VCaP cells of the region of chromosome 21 that covers the TFF3 gene and ∼30 kb of upstream sequence and ∼6.5 kb of
sequence downstream from the last exon. The lines indicate the relative number of significant reads that mapped to the indicated region.
The chromosome region is indicated above. The normalized peak reading (47.6) and the cutoff reading (6.4; above which is defined
as significant) are shown on the left. (C) Bar graphs showing the amount of enriched DNA (relative to input chromatin preparation) that
correspond to the indicated EBS in a HNPC, metastatic (M) prostate cancer, or benign tissue samples after ChIP using rabbit anti-ERG or
rabbit anti-ERG or rabbit IgG antibodies. Error bars, SD across triplicate experiments.
Figure W3. Stable overexpression of tERG in RWPE-1 cells (RWPE1-
tERG). This graph shows the relative levels of tERG or TFF3 mRNA
in stable RWPE1-tERG cells comparedwith RWPE1-GFP control cells.
These cells correspond to the cells treated with androgen shown in
Figure 4B.
